ArticleNeuroradiology2025
Neuroimaging characteristics of single Large-Scale mitochondrial DNA deletion syndromes.
Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeSingle large-scale mitochondrial DNA deletion syndromes (SLSMDSs) are rare mitochondrial disorders that present a continuum of phenotypes, including Pearson syndrome, Kearns-Sayre syndrome, and progressive external ophthalmoplegia. Neuroimaging findings in SLSMDSs are underreported, and their role in diagnosis and disease monitoring remains inadequately defined. This study aims to characterize clinical features and analyze neuroimaging findings, including spectroscopy and diffusion imaging, in patients with SLSMDSs.
methodsA retrospective review of 11 patients diagnosed with SLSMDSs at a tertiary referral center between 2013 and 2024 was conducted. Clinical, genetic, and neuroimaging data were analyzed. MRI scans were reviewed for abnormalities in various brain regions, including white matter, basal ganglia, thalami, corpus callosum, cerebellum, and brainstem.
resultsThe cohort had a mean age of 8.3 years (63.6% female). MRI was normal in 4 patients. Among the remaining 7, symmetrical T2/FLAIR hyperintensities, with or without diffusion alterations, were frequently observed, involving the dorsal brainstem in 7/7 and the cerebellum in 6/7 of patients. Globi pallidi involvement was also present in 6 of 7 patients. MR basal ganglia spectroscopy demonstrated elevated lactate in 3 of 7 patients with available spectroscopy. Subcortical and deep white matter abnormalities were identified in 3 patients, sparing the periventricular regions. Imaging progression was noted in patients with serial studies (4 patients).
conclusionsNeuroimaging in SLSMDSs typically demonstrates characteristic involvement of the dorsal brainstem, cerebellum, and basal ganglia, and may show diffusion alterations, a finding suggestive of metabolic injury. The observed pattern of subcortical white matter involvement with periventricular sparing may aid in differentiating this disorder from others. Normal imaging may be present in early or less severe disease. MRI, including diffusion imaging and spectroscopy, can support diagnosis and longitudinal monitoring.
Indexed as
Identifiers
40637848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.